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ABSTRACT 
Objective: The present work aimed to develop a simple, rapid, specific and precise liquid chromatography-tandem mass spectrophotometric (LC–
MS/MS) validated method for quantification of pomalidomide and internal standard (ISTD) Fluconazole in human plasma. 
Methods: 50 µl of 0.1% formic acid was added to plasma samples prior to liquid-liquid extraction (LLE) using 2.5 ml of ethyl acetate. 
Chromatographic separation was achieved on Xterra, RP18, 5 µ (50 x 4.6 mm) column using a mixture of 0.1% (v/v) formic acid in water to methanol 
at a ratio of 12:88, v/v as the mobile phase. The flow rate was 0.50 ml/min. The LC eluent was split, and approximately 0.1 ml/min was introduced 
into Tandem mass spectrometer using turbo Ion Spray interface at 325 °C. Quantitation was performed by transitions of m/z 260.1 precursor ion to 
the m/z 148.8 for pomalidomide and m/z 307.1/238.0 for fluconazole. 
Results: The concentrations of nine working standards showed linearity between 9.998 to 1009.650 ng/ml (r2 ≥ 0.9968). Chromatographic 
separation was achieved within 2 min. The average extraction recoveries of three quality control concentrations were 53.86% for pomalidomide 
and were within the acceptance limits. The coefficient of variation was ≤15% for intra-and inter-batch assays. The %CV of ruggedness ranges 1.32 
to 4.03. The % stability of short term and long term stock solution stability studies was found to be 99.01% and 98.49% respectively.  
Conclusion: The results obtained for specificity, linearity, accuracy, precision, ruggedness and stability studies were within limits. Thus the 
validated economical method was applied for pharmacokinetic studies of pomalidomide. 
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INTRODUCTION 
Pomalidomide chemically 4-amino-2-(2, 6-dioxopiperidin-3-yl) 
isoindoline-1, 3-dione, the newest immune-modulatory drugs (IMiD), 
was designed to be more potent and less toxic than thalidomide and 
lenalidomide [1-2]. It is used for the treatment of relapsed and refractory 
multiple myeloma. Dr. Rober D'Amato's labs led to the first report [3-4] 
stating that 3-amino-thalidomide was able to directly inhibit both the 
tumor cell and vascular compartments of myeloma cancers. An HPLC-UV 
method was reported for inversion of pomalidomide in phosphate-
buffered saline and human plasma in μg/ml range [5]. The LC-MS 
methods were also published for the Pharmacokinetic study of 
pomalidomide but no validation details were presented [6-7]. A 
validated UPLC-MS method was reported using negative ionisation 
mode for determination of pomalidomide from rat plasma [8], Described 
here is a simple, sensitive, and selective LC-MS/MS method for 
pomalidomide in the human plasma concentration range of 9.998 to 
1009.650 ng/ml. As there is no literature on stability data of 
pomalidomide in human plasma, this study performed assay validations, 
according to the FDA guidelines [9]. While this method with validation 
details were economical and applied for pharmacokinetic studies of 
pomalidomide. 
MATERIALS AND METHODS [8] 
Apparatus and software 
The HPLC pump (Agilent 1200 series Binary SL) with an 
autosampler (Agilent 1200 series Hip-ALSSL) was coupled with 
Agilent 6460 Triple Quad Tandem mass spectrometer. The column 
oven was Agilent 1200 series TCC SL. The chromatographic 
integration was performed by Agilent mass hunter software. 
Chemicals and reagents 
Pomalidomide and Fluconazole (IS) were procured from NATCO 
Pharma Ltd., Hyderabad, Formic acid, Methanol and ethyl acetate 
was procured from Merck Specialities Pvt. Ltd, Mumbai, India. Water 
used was collected from water purification systems (Milli Q, Milli 
Pore, USA) installed in the laboratory. Pooled drug-free expired 
frozen human plasma (K2-EDTA as anticoagulant) was obtained 
froma Blood Bank, Hyderabad, was used during validation and study 
sample analysis. The plasma was stored into-70±5 °C. 
Standards and working solutions 
Calibration standard solutions 
Stock solutions of pomalidomide and Fluconazole internal standard (IS) 
were prepared in methanol. Further dilutions were carried out in 50% 
methanol. Calibration standards of nine concentration levels were 
prepared freshly by spiking drug-free plasma with pomalidomide stock 
solution to give the concentrations of 9.998, 25.241, 50.281, 150.438, 
301.885, 503.815, 705.745, 906.666 and 1009.650 ng/ml. 
Quality control standards 
Lowest quality control standards, Median quality control standards 
and highest quality control standards were prepared by spiking 
drug-free plasma with pomalidomide to give a solution containing 
26.248, 323.056 and 807.640 ng/ml respectively. They were stored 
at-20 °c till the time analysed. 
Chromatographic conditions 
Chromatographic separation was performed on Xterra, RP18, 5 µ (50 x 
4.6 mm), analytical column and the mobile phase was a mixture of 0.1% 
(v/v) formic acid in water to methanol at a ratio of 12:88, v/v. Injection 
volume was 10μL. The flow rate was 0.50 ml/min. Total analysis time of 
single injection was 2.0 min. Column oven temperature and autosampler 
temperature was set to 30 °C and 10 °C, respectively. 
Mass spectrometric conditions 
The LC eluent was split, and approximately 0.100 ml/min was 
introduced via electrospray ionisation using a Turbo Ion Spray 
interface set at 325 °C to generate positive ions [M+H]+. The Mass 
spectrometric parameters were optimised as shown in table no 1. 
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Table 1: Mass spectrometric conditions 
Capillary voltage 3500V 
Nozzle voltage 1500V 
Delta EMV(+) 500 Positive 
Gas flow 5 L/min 
Gas temperature 350 °C 
Nebulizer pressure 25 psi 
Sheath gas temperature 300 °C 
Sheath gas flow 11L/min 
Acquisition 
Parameters Pomalidomide ISTD  
Transition 260.1/148.8 (m/z) 307.1/238.0 (m/z) 
Polarity Positive Positive 
MS1 resolution Unit Unit 
MS2 resolution Unit Unit 
Dwell time (millisec) 200 200 
Fragmentor (V) 100 100 
Collision energy (V) 8 10 
 
Sample preparation method 
To 250 µl of plasma, 50 µl of ISTD (1µg/ml) and 50 µl of 0.1% formic 
acid was added and vortexed. The drug was extracted with 2.5 ml of 
ethyl acetate, followed by centrifugation at 2000 rpm/min on a 
cooling centrifuge for 15 min at 4 °C. The supernatant of 2 ml was 
withdrawn and evaporated at 50 °C 15 psi of nitrogen until dryness 
at LV evaporator. The residue was reconstituted with 500 µl of 
mobile phase and respective samples were injected into the column. 
Validation 
Specificity 
A solution containing 9.999 ng/ml was injected onto the column under 
optimised chromatographic conditions to show the separation of 
pomalidomide from impurities and plasma. The specificity of the method 
was checked for the interference from plasma. 
Linearity 
Spiked concentrations were plotted against peak area ratios of 
pomalidomide to the internal standard, and the best fit line was 
calculated. Wide range calibration was determined by solutions 
containing9.998 to 1009.650ng/ml. 
Recovery studies 
The % mean recoveries were determined by measuring the responses of 
the extracted plasma Quality control samples at HQC, MQC and LQC 
against un-extracted Quality control samples at HQC, MQC and LQC. 
Precision and accuracy 
The between-run (Inter-day) accuracy and precision evaluation 
were assessed by the repeated analysis of human K3 EDTA plasma 
samples containing different concentrations of pomalidomide on 
separate occasions. A single run consisted of a calibration curve plus 
six replicates of the lower limit of quantitation, low, medium and 
high-quality control samples. 
Within-run (Intraday) accuracy and precision evaluations were 
performed by analysing replicate concentrations of pomalidomide in 
human K3 EDTA plasma. The run consisted of a calibration curve 
plus a total of 24 spiked samples, six replicates of each of the LLOQ, 
lower, medium and higher quality control samples. 
Matrix effect 
Blank plasma samples of 6 different human K3 EDTA plasma sources 
were processed and spiked with aqueous low-quality control and high-
quality control (post extraction addition) and analysed in a single run 
along with diluted pure standard at each concentration level. 
Ruggedness 
The ruggedness of the method was assessed by analysing a precision and 
accuracy batch using a different column, by the different analyst in 
another instrument. 
Stability studies 
Short-term stock solution stability of pomalidomide 
Solutions of pomalidomide were prepared in methanol (Stability 
Samples) and were kept at room temperature for 6 h 30 min. A 
freshly prepared solution of pomalidomide (Comparison Samples) 
and stability samples were diluted at approximately the same 
analyte concentration and analysed in a single run; analyte 
responses were used to determine % stability over time. 
Short-term stock solution stability of internal standard 
Solutions of internal standard (Fluconazole) were prepared in methanol 
(Stability Samples) and were kept at room temperature for 6 h 30 min. A 
freshly prepared solution of internal standard (Comparison Samples) 
and stability samples were diluted at approximately the same analyte 
concentration and analyzed in a single run; Analyte responses were used 
to determine % stability over time. 
Freeze-thaw stability 
Samples were prepared at low and high-quality control levels, 
aliquoted and frozen at-70 °C. Some of the aliquots of quality control 
samples were subjected to five freeze-thaw cycles (stability 
samples). A calibration curve and quality control samples were 
freshly prepared (Comparison Samples) and processed with 6 
replicates of stability samples and analysed in a single run. 
Long-term stock solution stability of pomalidomide 
Solutions of Pomalidomide were prepared in methanol (Stability 
Samples) and were kept at refrigerator (2-8 °C) for 10 D 02 H. A 
freshly prepared solution of pomalidomide (Comparison Samples) 
and stability samples were diluted at approximately the same 
analyte concentration and analysed in a single run. 
Long-term stock solution stability of internal standard 
Solutions of Internal standard were prepared in methanol (Stability 
Samples) and were kept at refrigerator (2-8 °C) for 10 D 02 H. A 
freshly prepared solution of internal standard (Comparison 
Samples) and stability samples were diluted at approximately the 
same analyte concentration and analysed in a single run 
RESULTS AND DISCUSSION 
The chromatography observed during the course of validation was 
acceptable and representative chromatograms of, LLOQ, LQC, MQC, 
HQC, internal standard (ISTD) and standard blank samples are 
shown in (fig. 1). 
The method developed was validated for specificity, accuracy and 
precision, linearity, ruggedness and stability as per USFDA guidance 
[10-12]. The results of validating parameters are given below. 
Specificity 
Nine different lots of plasma were analysed to ensure that no 
endogenous interferences were present at the retention time of 
pomalidomide and fluconazole. Nine LLOQ (9.999 ng/ml) level samples 
along with plasma blank from the respective plasma lots were prepared 
and analysed. (table 2) shows results of specificity. In all plasma blanks, 
the response at the retention time of pomalidomide was less than 20% 
of LLOQ response, and at the retention time of IS, the response was less 
than 5% of mean IS response in LLOQ. The typical chromatogram of 
plasma blank and chromatogram of LLOQ was shown in (fig. 1). 
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Fig. 1: Chromatograms of LLOQ, quality control samples, ISTD and blank matrix 
 
Table 2: Results of specificity for pomalidomide and fluconazole (ISTD) 
 Analyte IS 
Area of interfering 
peak at RT of analyte 
Area observed for 
extracted LLOQ 
% Interference at 
RT of analyte 
Area of interfering 
Peak at RT of ISTD 
Area observed for 
extracted ISTD 
% Interference at 
RT of ISTD 
01 0 15286 0 0 575244 0 
02 0 13288 0 0 582214 0 
03 0 11110 0 0 578922 0 
04 0 11440 0 0 564562 0 
05 0 11402 0 0 558925 0 
06 0 11059 0 0 589001 0 
07 0 11215 0 0 591285 0 
08 0 11580 0 0 578862 0 
09 0 12089 0 0 588638 0 
Mean 12052.111 MEAN 180201.89  
 
Linearity 
The calibration curve (peak area ratio Vs Concentration) was 
linear over working a range of 9.998 to 1009.650 ng/ml with 
nine point calibration used for quantification by linear 
regression, shown in (fig. 2). The regression equation for the 
analysis was Y=0.0039x-0.0089 with coefficient of correction 
(r2) = 0.99686. 
 
 
Fig. 3: Spiked concentrations (9.998 to 1009.650 ng/ml) were plotted against calculated concentration Vs concentration with ten point 
calibration used for quantification by linear regression 
 
Recovery 
The % mean recovery for pomalidomide in LQC, MQC and HQC was 50.68%, 53.43% and 57.49% respectively (table 3). 
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Table 3:% Mean recovery of pomalidomide for LQC, MQC and HQC 
 LQC 26.248ng/ml MQC 323.056 ng/ml HQC 807.640 ng/ml 
Aqueous analyte 
response 
Extracted analyte 
response  
Aqueous analyte 
response 
Extracted analyte 
response  
Aqueous analyte 
response 
Extracted analyte 
response  
01 240986 49902 2785844 599122 6694089 1549621 
02 245029 49079 2784946 595935 6765199 1550584 
03 244894 48906 2792062 593232 6782112 1564921 
04 243537 48828 2785487 591894 6835789 1571431 
05 240892 49190 2779585 593165 6838061 1568923 
06 238416 48789 2785210 598329 6870744 1573663 
Mean 242292.3 49115.6 2785522.3 595279.5 6797665.6 1563190.5 
SD (+) 2626.8 414.3 3963.6 2987.2 63952.7 10549.7 
CV (%) 1.08 0.84 0.14 0.50 0.94 0.67 
Conc. Factor 250 250 250 
Mean Recovery  50.68 53.43 57.49 
Global 
Recovery  
53.86 
 
Intraday (within run) and inter-day (between run) precision 
and accuracy 
The within-run coefficients of variation ranged between 1.47% and 
4.57% for pomalidomide. The within-run percentages of nominal 
concentrations ranged between 97.95% and 107.58% for 
pomalidomide. Results are presented in table 4. 
The between-run coefficients of variation ranged between 2.88% 
and 4.22% for pomalidomide. The between-run percentages of 
nominal concentrations ranged between 99.41% and 106.97% for 
pomalidomide. Results are presented in table 5. 
Matrix effect 
The percentage matrix effect of analyte was found to be-0.25 and 
2.74 for pomalidomide for low and high-quality control samples. 
Results are presented in table 6. 
Ruggedness 
The coefficients of variation ranged between 1.32% and 4.03% for 
pomalidomide. The percentages of nominal concentrations ranged 
between 101.06% and 110.08% for pomalidomide. Results are 
presented in table 7. 
 
Table 4: Intraday precision and accuracy of quality control standard 
 S. N0. LLOQ 9.999 ng/ml LQC 26.248ng/ml MQC  323.056 ng/ml HQC 807.640 ng/ml 
Conc. found 
(ng/ml) 
% nominal 
Conc 
Conc. found 
(ng/ml) 
% nomi 
Conc nal  
Conc. found 
(ng/ml) 
% nominal 
Conc  
Conc. found 
(ng/ml) 
% nominal 
Conc  
 1 10.705 107.06 28.081 106.98 315.669 97.71 762.368 94.39 
 2 10.569 105.70 27.895 106.27 355.681 110.10 782.178 96.85 
 3 10.411 104.12 27.857 106.13 318.659 98.64 775.543 96.03 
 4 11.487 114.88 27.942 106.45 324.372 100.41 810.934 100.41 
 5 10.61 106.11 27.841 106.07 317.699 98.34 805.069 99.68 
 6 10.758 107.60 28.915 110.16 327.842 101.48 810.606 100.37 
N 6 6 6 6 6 6 6 6 
Mean 10.757 107.58 28.089 107.01 326.654 101.11 791.116 97.95 
SD(±) 0.38   0.41   14.93   20.57   
CV(%) 3.51 1.47 4.57 2.60 
 
Table 5: Inter day precision and accuracy of quality control standard 
Batch ID LLOQ 9.999 ng/ml LQC 26.248ng/ml MQC 323.056 ng/ml HQC 807.640ng/ml 
Conc. found 
(ng/ml) 
% nominal 
conc 
Conc. found 
(ng/ml) 
% nominal 
conc 
Conc. found 
(ng/ml) 
% nominal 
conc 
Conc. found 
(ng/ml) 
% nominal 
conc 
 10.705 107.06 28.081 106.98 315.669 97.71 762.368 94.39 
 10.569 105.70 27.895 106.27 355.681 110.10 782.178 96.85 
PandA-
01 
10.411 104.12 27.857 106.13 318.659 98.64 775.543 96.03 
 11.487 114.88 27.942 106.45 324.372 100.41 810.934 100.41 
 10.610 106.11 27.841 106.07 317.699 98.34 805.069 99.68 
 10.758 107.60 28.915 110.16 327.842 101.48 810.606 100.37 
 10.322 103.23 27.867 106.17 311.270 96.35 762.021 94.35 
 10.385 103.86 26.741 101.88 355.184 109.95 783.091 96.96 
PandA-
02 
10.609 106.10 26.569 101.22 315.344 97.61 762.157 94.37 
 10.896 108.97 27.498 104.76 312.676 96.79 798.395 98.86 
 10.268 102.69 27.581 105.08 313.590 97.07 786.741 97.41 
 10.307 103.08 27.235 103.76 317.332 98.23 793.101 98.20 
 10.729 107.30 28.810 109.76 330.628 102.34 775.171 95.98 
 10.867 108.69 28.880 110.03 318.223 98.50 838.267 103.79 
PandA-
03 
10.309 103.10 29.561 112.62 326.177 100.97 830.304 102.81 
 10.321 103.22 29.126 110.97 328.816 101.78 874.482 108.28 
 10.805 108.06 29.018 110.55 327.572 101.40 854.598 105.81 
 10.443 104.44 27.968 106.55 327.423 101.35 846.592 104.82 
N:  18 18 18 18 18 18 18 18 
Mean:  10.600 106.01 28.077 106.97 324.675 100.50 802.868 99.41 
SD(±): 0.31  0.83  12.76  33.89  
CV (%): 2.88 2.95 3.93 4.22 
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Table 6: Results of matrix effect obtained by preparing LQC and HQC with six different lots of plasma 
S. No. AQS LQC response PEX LQC  response AQS HQC response PEX HQC response 
1 195688 203204 5680638 5635662 
2 200736 197892 5694436 5694225 
3 200626 197423 5637040 6355785 
4 198973 198785 5647571 5716531 
5 200778 199084 5680208 5753628 
6 201077 198505 5655245 5772353 
Mean 199646.333 199148.833 5665856.333 5821364 
SD 2078.29 2076.23 22443.71 266171.21 
%CV 1.04 1.04 0.4 4.57 
%ME -0.25   2.74   
 
Table 7: Results of ruggedness 
S. No. LLOQ 9.999 ng/ml LQC 26.248ng/ml MQC 323.056 ng/ml HQC 807.640 ng/ml 
Conc. found 
(ng/ml) 
% nominal 
conc 
Conc. found 
(ng/ml) 
% 
nominal  conc 
Conc. found 
(ng/ml) 
% nominal 
conc  
Conc. found 
(ng/ml) 
% nominal 
conc  
 1 10.729 107.30 28.810 109.76 330.62 102.34 775.171 95.98 
 2 10.867 108.69 28.880 110.03 318.22 98.50 838.267 103.79 
 3 10.309 103.10 29.561 112.62 326.17 100.97 830.304 102.81 
 4 10.321 103.22 29.126 110.97 328.81 101.78 874.482 108.28 
 5 10.805 108.06 29.018 110.55 327.57 101.40 854.598 105.81 
 6 10.443 104.44 27.968 106.55 327.42 101.35 846.592 104.82 
N 6 6 6 6 6 6 6 6 
Mean 10.579 105.80 28.894 110.08 326.47 101.06 836.569 103.58 
SD(±) 0.25   0.53   4.31   33.69  
CV (%) 2.37 1.82 1.32 4.03 
 
Stability studies 
Short-term stock solution stability of pomalidomide 
Pomalidomide is found to be stable in methanol for 6 h 30 min at room 
temperature with a % stability of 99.01%. Results are presented in table 8. 
Short-term stock solution stability of internal standard 
The internal standard is found to be stable in methanol for 6 h 30 
min at room temperature with a % stability of 99.15%. Results are 
presented in table 9. 
Freeze-thaw stability 
Pomalidomide is found to be stable in human K3 EDTA plasma after 
five freeze-thaw cycles at-70 °C with coefficients of variation of 
3.27% (LQC) and 3.86% (HQC) for pomalidomide, and the 
percentages of nominal concentrations for pomalidomide were 
found to be 103.17% (LQC) and 101.23% (HQC). Results are 
presented in table 10. 
Long-term stock solution stability of pomalidomide 
Pomalidomide is found to be stable in methanol 10 D 02 H at 
refrigerator (2-8 °C) with a % stability of 98.49% for pomalidomide. 
Results are presented in table 11. 
Long-term stock solution stability of internal standard 
The internal standard is found to be stable in methanol 10 D 02 H at 
refrigerator (2-8 °C) with a % stability of 97.74%. Results are 
presented in table 12. 
 
Table 8: Short-term stock solution stability of analyte 
S. No. Analyte 
SS CS 
1 2564444 2606664 
2 2597482 2616699 
3 2606795 2630379 
4 2611068 2627041 
5 2598633 2630048 
6 2608998 2629280 
Mean 2597903.333 2623351.833 
SD 17295.66 9651.08 
%CV 0.67 0.37 
% stability 99.01 
 
Table 9: Short-term stock solution stability of internal standard 
S. No. ISTD 
Stability solution Comparison solution 
1 2504198 2521525 
2 2510082 2524682 
3 2498215 2537401 
4 2487925 2519696 
5 2512367 2504040 
6 2491004 2526432 
Mean 2500631.833 2522296.000 
SD 9997.37 10877.47 
%CV 0.40 0.43 
% stability 99.15 
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Table 10: Freeze-thaw stability at-70 °C 
S. No. Freshly spiked Freeze-thaw 
LQC HQC LQC HQC 
Nominal Con (ng/ml) Nominal Con (ng/ml) 
26.249 807.648 26.248 807.64 
1 28.019 791.749 29.380 801.458 
2 27.816 767.862 30.051 839.017 
3 27.327 789.495 28.055 824.962 
4 27.830 821.854 27.867 754.842 
5 27.819 842.104 28.198 791.864 
6 27.272 770.159 27.791 830.043 
Mean 27.680 797.204 28.557 807.031 
SD 0.31 29.34 0.93 31.17 
%CV 1.10 3.68 3.27 3.86 
% stability 103.17 101.23 
 
Table 11: Long-term stock solution stability of analyte 
S. No. Analyte 
SS CS 
1 2280682 2314048 
2 2287758 2311173 
3 2291699 2307848 
4 2288329 2312386 
5 2300006 2324564 
6 2287308 2353235 
Mean 2280682 2314048 
SD 6355.03 16985.98 
%CV 0.28 0.73 
% stability 98.49 
 
Table 12: Long-term stock solution stability of internal standard 
S. No. ISTD 
Stability solution Comparison solution 
1 2458845 2520014 
2 2448795 2531462 
3 2431526 2512650 
4 2484415 2526423 
5 2478462 2513284 
6 2460025 2500186 
Mean 2460344.7 2517336.5 
SD 19359.133 11151.5822 
%CV 0.79 0.44 
% stability 97.74 
  
CONCLUSION 
Chromatographic separation was achieved on Xterra, RP18, 5 µ (50 x 
4.6 mm) column using a mixture of 0.1% (v/v) formic acid in water to 
methanol at a ratio of 12:88, v/v as the mobile phase. The drug was 
extracted with 2.5 ml of ethyl acetate. The specificity of the method 
was checked for the interference from plasma. The calibration curve 
(peak area ratio Vs Concentration) was linear over working a range of 
9.998 to 1009.650 ng/ml with nine point calibration used for 
quantification by linear regression. The % mean recovery for 
pomalidomide in LQC, MQC and HQC was 50.68%, 53.43% and 
57.49% respectively. The within-run coefficients of variation ranged 
between 1.47% and 4.57% for pomalidomide. The between-run 
coefficients of variation ranged between 2.88% and 4.22% for 
pomalidomide. The percentage matrix effect of analyte was found to 
be-0.25 and 2.74 for pomalidomide for low and high-quality control 
samples. The stability test was performed to assess the long term and 
short term stability of sofosbuvir sample solutions, internal standard 
solutions. The developed method was validated for the quantitative 
determination of sofosbuvir from plasma was simple, rapid, specific, 
sensitive, accurate and precise. Hence, the method is quite suitable to 
detect the drug from plasma samples of human volunteers. 
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